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Abstract
Violation of the heart rhythm is widespread at present. Anxiety-depressive symptoms and a tendency to chronic stress 
leads to the depletion of the body, which contributes to arrhythmia.
The aim of the study is to assess the severity of clinical and hemodynamic indices by using anxiolytic drug mebicar. 
Materials and methods. Assessment of psycho-emotional status was studied using the psychosocial scale of stress by 
L. Reader, PSS-10 PHQ-15 and questionnaire identification of social factors that can affect health. Determination of cortisol level 
in serum was carried out by immunoassay (ELISA) on the ER-500 Microplate Reader. The concentration of N-terminal fragment 
of the brain natriuretic peptide precursor (NTproBNP) in serum was determined by ELISA using a Biosan PST-60HL shaker. 
Results. The results of the survey showed a direct dependence of the manifestation of atrial fibrillation (AF) on the level of 
psychoemotional stress. We found that in group 1b (standard treatment+mebicar) there were complaints of increased excitability 
(p<0.001), (p-reliability difference of indices before and after treatment), fatigue (p<0.001), deterioration of memory (p<0.01), 
appetite loss (p<0.05), sleep disturbance (p<0.001), signs of severe sweating (p<0.001), indicating the appearance of astheno-veg-
etative syndrome. The reduction of manifestations of high stress (p<0.01) in patients of group 1b (standard treatment+mebicar) 
was noted. A similar pattern was detected in the severity of anxiety in men (p<0.01).
Conclusions. Application in the complex therapy of patients with stable coronary heart disease (SIHD) in conjunction 
with AF anxiolytics of the benzodiazepine series (mebicar) has allowed stopping anxiety-depressive disorders. Analyzing the lev-
el of cortisol, we observed its increase depending on the degree of anxiety and depression; NT-proBNT metrics are respectively. 




Atrial fibrillation (AF) is the most commonly persistent cardiac arrhythmia in clinical prac-
tice, which contributes to a deterioration in the quality of life, increased morbidity and mortality 
[1]. Anticipated by 2030 due to risk factors such as obesity and diabetes [2], arrhythmia [3], arterial 
hypertension [4], more than 23,3 million people will die from acute myocardial infarction (MI), 
stroke, [2] systemic embolism [3] and life-threatening cardiovascular disorders [5]. 
Among the population of Ukraine, cardiovascular disease (CVD) accounts for 63.3 % of 
all fatal cases [6]. Significant groups of the population have mental disorders, including post-trau-
matic stress disorder (PTSD) and disorders of adaptation. Their prevalence in the population 
is: PTSD – 1–3 %, adaptive disorders – 5–20 % of all patients. In the structure of morbidity, 
non-psychotic mental disorders prevail – neuroses, reactions to stress, personality disorders [7]. 
Anxiety-depressive symptoms [5], negative emotions [8], and the impact of chronic stress 
were considered by cardiologists and psychiatrists a long time ago [9]. For many decades, the theo-
ry of psychosomatic heart disease has been formed [9]. Clinical trials have been conducted to study 
the role of depression, anger, anxiety and chronic stress with AF incidents. MESA (Multi-Ethnic 
Study of Atherosclerosis) has confirmed the association of anxiety-depressive states with an in-
creased risk of AF [10, 11]. Therefore, there is a relationship between AF and these states [12], but 
the spectrum of psychological disorders remains unclear [13]. 
Original Research Article:
full paper




As a rule, stress-induced rhythm disturbance is manifested by tachyarrhythmias char-
acterized by a pathologically rapid rhythm. Conditionally, they can be divided into organic-as-
sociated with any pathology of the heart muscle or vessels, most often it is SIHD, myocardial 
infarction, myocarditis, cardiosclerosis, cardiomyopathies and inorganic (functional) – have 
no basis for organic lesions, the main causes of their development there are physical and psy-
chological overload, emotional shock, frequent stress situations, intoxication, hypoxia, alco-
hol, smoking [9]. 
It is suggested that personal psychology and the presence of psychological distress may 
be due to the influence on the sympathetic nervous system, systemic and regional inflamma-
tion, and the endothelium function to be factors contributing to the development of AF [13]. 
The interaction of the cardiovascular and nervous system is a complicated algorithm in a state 
of rest, and in the period of stress these reactions become even more complex and dynamic. 
Negative emotions lead to coronary ischemia, platelet activation, changes in hemodynamics 
and the release of catecholamines in the blood, as well as cause electrical dissociation in the 
atria and ventricles [9]. 
The mechanisms underlying both initiation and the onset of AF are not sufficiently estab-
lished, but they are believed to include inflammation and oxidative stress [1]. There is a strong ev-
idence that there is a strong correlation between inflammation and the pathogenesis of AF [1, 3]. 
Various inflammatory markers (C-reactive protein, tumor necrosis factor-, interleukin-2, interleu-
kin-6, interleukin-8) were associated with AF. These include the activation and damage of the 
endothelium, the production of tissue factor from monocytes, increased platelet activation and 
fibrinogen expression [3]. Oxidative stress is characterized the inability of the cell to overcome the 
increase in the release of reactive oxygen species and prevent damage to cellular structures as a 
result of this increase. Excessive development of which can lead to damage to the oxidative tissue 
of the myocardium. 
Natriuretic peptide B-type (BNP) is synthesized by ventricular cardiomyocytes in the 
form of preproBNP precursor proteins. The main stimulus of its secretion is increased pressure 
of the myocardium with increasing pressure in the left ventricle of the heart. Subsequent-
ly, preproBNP is cleaved and released into the blood in the form of N terminal fragment – 
NTproBNP and active hormone – BNP. High concentration and stability in serum allows using 
NTproBNP to evaluate the function of the myocardium [2]. Investigated the content of gluco-
corticoid hormones in biological f luids, which are objective criteria for the level of acute stress 
and the type of response of the body to the psycho-emotional stress. After all, psycho-emo-
tional stress is associated with an increased content of cortisol, which is associated with anx-
iety-depressive symptoms [8]. Violation of adequate interaction between the cardiac muscle 
and the above listed structures in response to emotional stress increases the risk of arrhythmia 
and sudden cardiac death [9]. 
Therefore, the main task is correction of pharmacological and psychotherapeutic methods 
of treatment. One of the few drugs that meets these needs is a mebicar, which is used in clinical 
practice. It has a wide clinical and pharmacological spectrum of action, suppresses feelings of fear, 
emotional tension, anxiety and anxiety, improve memory and intellectual activity. Daily dosage – 
500 mg twice a day, regardless of food intake [11]. 
The аim of research is to evaluate the effectiveness of treatment with mebicar in patients 
with permanent atrial fibrillation.
2. Materials and methods
31 medical records of patients undergoing treatment at the cardiology department of the 
regional clinical cardiology center in Ivano-Frankivsk were examined. All patients were divided 
into 2 groups: 1a – patients with SIHD with a constant form of AF who received standard therapy 
(16 patients were examined), 1b – patients with SIHD with permanent form of AF form that had 
anxiolytic therapy in the complex treatment (15 patients were examined). Prior to treatment, the 
groups did not differ from each other, during controlled treatment, the standard treatment group 
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received antihypertensive therapy (angiotensin-converting enzyme inhibitor or sartans), anticoag-
ulant therapy (warfarin, dabigatran), β-blockers (bisoprolol, metoprolol, nebivolol), lipid-lowering 
drugs (statins), and in group 1b, in addition to standard therapy, mebіcar was prescribed twice daily 
during the treatment period. The duration of controlled follow-up lasted 2 weeks. The study was 
conducted from February 26, 2018 to January 28, 2019.
Criteria for inclusion in the study: signed informed consent to participate in the study; per-
manent form of AF, documented on an electrocardiogram (ECG). Criteria for exclusion from the 
study: incapable patients for the psycho-neurological condition; acute conditions (acute coronary 
syndrome, myocarditis, pulmonary artery thromboembolism, life-threatening rhythm disturbanc-
es (persistent ventricular tachycardia, ventricular fibrillation); reversible causes of AF, such as 
thyrotoxicosis, alcohol intoxication. 
All surveyed signed informed consent to participate in the study in accordance with the 
World Health Association Declaration of Helsinki. The study was approved by the Commission 
on Ethical Principles of Ivano-Frankivsk National Medical University No. 120/20 from 21.05.20. 
All surveyed were evaluated for stress according to the methodology of the psychosocial 
stress scale by L. Reeder. Questionnaire of L. Reeder included 7 questions and 4 possible an-
swers to each question. The level of stress was assessed as low (0.00–0.99 points), mean (1.00– 
1.99 points) and high (2.00–3.00 points) stress in men and women (0.00–1.17 points), (1.18–2.17 
points) and (2.18–3.00 points), respectively. The scale of perceived stress – 10, included 10 points, 
divided by the level of stress, where 0-13 corresponds to the position “low”, 14–16 – “medium”, and 
27–40 – “high”. The PHQ-15 consists of 13 points that are used to diagnose somatoform disorder. 
The questionnaire for identifying social factors that may affect health includes 28 points. Hospital 
scale HADS was used to assess the degree of anxiety and depression. The questionnaire for the de-
tection of the status of anxiety and depression presented 7 questions with 3 variants of the answer. 
Interpretation of these results allows to differentiate 3 categories of the state: norm, subclinical and 
clinical level. 0–7 points – norm, no dealings; 8–10 – possible case of anxiety/depression; 11 or 
more is a likely case of anxiety/depression. 
Quantitative determination of catalase by A. Bach and S. Zubkova was carried out by 
titration using hydrogen peroxide, sulfuric acid, potassium permanganate, distilled water and 
patient blood. The activity of superoxide dismutase was determined on the device KFK-2MP 
device, the principle of determination is based on the establishment of nitrotetrazole by su-
peroxide radicals formed by the reaction between phenazine metasulfate and a certain form of 
nicotinamide dinucleotide. Reagents used for this purpose: 0.15 M phosphate buffer (pH 7.8), 
incubation mixture – 37 ml of EDTA-Na2 (ethylenediaminetetraacetate disodium salt), 330 ml 
of nitrotetrazole blue, 55 ml of phenazine metasulfate. This mixture was mixed with 300 ml 
of phosphate buffer and left overnight, filtered in the morning. The calculation was performed 
according to the formula: 
SOD (%)=Ek–EO:Ek×100.
The activity of glutathione peroxidase (GP) was determined on an apparatus on SPE-
CORDM40, using a reaction mixture comprising - 1 ml of phosphate buffer, azide Na 12 mm – 
0.9 ml, 0.5 ml – 2.5 mm reduced glutathione, 0.2 ml of serum of the patient’s blood, 0.5 ml of 
H2O2. The reaction was started by adding H2O2, stopped after 2 minutes by adding 1 ml of 10 % 
trichloroacetic acid. Centrifuge at 3000 rpm for 15 minutes. Determined the extinction of oxidized 
glutathione at 260 nm. The enzyme activity was expressed in micromoles of oxidized glutathione 
per 1 g Hb per minute. 
The quantitative determination of the concentration of total cortisol in serum was deter-
mined by ELISA using the ER-500 Microplate Reader. Reagent kit 3625–300 Cortisol Test Sys-
tem, Monobind Inc., USA. The set of reagents included: calibrators cortisol – 1 ml/vials, enzyme 
reagent cortisol – 1.0 ml/vials, steroid conjugate buffer – 7.0 ml/vials, streptavidin-coated plate, 
wash solution concentrate – 20 ml, substrate A – 7 ml/vials, substrate B – 7 ml/vials, stop solution – 
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8 ml/vials. Reagents required for a solid-phase enzyme-linked immunosorbent assay include an-
tibodies, an enzyme conjugate with antigen and a native antigen. When mixing biotinylated an-
tibodies, the enzyme-antigen conjugate and the native antigen contained in the serum, there is 
a competition between the native antigen of the sample and the enzyme-antigen conjugate for a 
limited number of immobilized binding sites.
 The content of N-terminal fragment concentration of the brain natriuretic peptide pre-
cursor (NTproBNP) in serum was determined by ELISA using a SINNOWAER-500 spectropho-
tometric analyzer using a Biosan PST-60HL shaker. Catalog number is А-9102. The firm – the 
manufacturer – BEST (Russia). The set includes calibration samples K1, K2, K3, K4 and K5 based 
on human serum, certified against the standard «Liquichek Cardiac Markers Plus Control» (firm 
BioRad, France), contain known amounts of NTproBNP; control sample based on human serum 
with known content NTproBNP, lyophilized – 1 bottle; conjugate of monoclonal antibodies to 
NTproBNP with horseradish peroxidase, concentrate-1 vial (0.7); dilution solution samples – 
1 vial (12.0 ml); solution for diluting the conjugate – 1 vial (13.0 ml); serum dilution solution – 
1 vial (12.0 ml); 25-fold concentrate of phosphate-buffered saline with twin (FSB-T25) – 1 vial 
(12.0 ml); tetramethylbenzidine plus solution (TMB plus solution), ready to use – 1 vial (12.0 ml); 
ready-to-use stop reagent – 1 vial (12.0 ml).
The statistical analysis of the results was carried out using the STATISTICA-10 program. 
The presence of differences between the studied indicators was assessed by Student’s test.
3. Results
A study conducted among patients with a permanent form of AF found that the risk of 
mental disorders in the absence of preventive and corrective measures increases significantly. 
Clinical manifestations occur within a month after a stressful situation, and the duration of 
symptoms does not exceed 6 months. Patients complained of general anxiety and dissatis-
faction with life, making impulsive, ill-considered decisions. Irritability, increased fear, ag-
gression, attacks of unfounded anger were noted. Impaired concentration and memory, poor 
performance, uncontrolled emotions, depression, and loss of desire to do something and strive 
for something.
After conducting a clinical examination in the relevant groups, we obtained the following 
results. Adaptation disorders (Table 1) in patients of group 1b with a high level of anxiety and 
depressive symptoms were characterized by astheno-vegetative syndrome. Analysis of the re-
sults confirmed signs of irritability (p<0.001), memory impairment (p<0.01), sleep disturbances 
(p<0.001), loss of appetite (p<0.05), signs of severe sweating (p<0.01), fatigue (p<0.001), which 
confirms the reliability of these indicators. It was noted that patients complained of intermittent 
sensations, rapid heartbeat, chest pain, which corresponded to the clinical picture of atrial fibril-
lation. In addition, in both study groups, the frequency of complaints of headache decreased 
from 75.0 % and 80.0 % of cases, up to the absence of manifestations (p<0.001). According to the 
objective examination, we found that in patients of both groups the symptoms corresponded to 
heart failure, due to shortness of breath at rest, edema of the lower extremities and acrocyanosis. 
Against the background of psychopharmacotherapy, patients noted the normalization of 
mood, improved sleep, recovery, recovery of interest in work, reducing the manifestations of 
astheno-autonomic syndrome. Therefore, after analyzing the clinical picture, we can say that the 
commitment to treatment with mebicar in patients of group 1b is reliably confirmed.
Comparison of the obtained data showed that in the group of patients receiving standard 
treatment in comparison with the group receiving mebicar in addition there were more people 
with low stress (43.75 % and 6.67 %, respectively, p>0.05). The level of high stress decreased 
significantly (p<0.001), respectively, the number of patients with moderate stress increased 
(p<0.01). It is interesting to note that among men signs of acute (divorce, death or serious ill-
ness of a loved one, lawsuit against a family member) and chronic (serious financial problems, 
long-term difficult relationship with a woman or children) psychosocial stress were much more 
common than among women (Table 2). 
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Clinical indices in patients with a permanent form of AF 
Indicators
Standard therapy 1a group (n=16) Standard therapy + mebicar 1b group (n=15)
Before treatment After treatment Before treatment After treatment
The feeling of interruptions 15 (93.75 %) 9 (56.25 %) p<0.05 10 (66.67 %)
1 (6.67 %) 
p<0.001
Accelerated heartbeat 10 (62.50 %) 5 (31.25 %) p>0.05 7 (46.67 %)
1 (6.67 %) 
p<0.001
Shortness of breath at rest 4 (25.0 %) – p<0.05 5 (33.33 %)
– 
p<0.001
Chest pain 5 (31.25 %) – p<0.05 6 (40.00 %)
1 (6.67 %) 
p<0.001
Increase blood pressure 8 (50.0 %) 2 (12.50 %) p<0.05 7 (46.67 %)
– 
p<0.01
Fatigue 13 (81.25 %) 8 (50.0 %) p>0.05 15 (100.0 %)
7 (46.67 %) 
p<0.001
Increased excitability – 1 (6.25 %) p>0.05 10 (66.67 %)
1 (6.67 %) 
p<0.001
Deterioration of memory 2 (12.50 %) 1 (6.25 %) p>0.05 7 (46.67 %)
– 
p<0.01
Frequent headaches 12 (75.0 %) – р<0.001 12 (80.00 %)
– 
p<0.01
Loss of appetite 2 (12.50 %) – р>0.05 5 (33.33 %)
– 
p<0.05
Sleep disturbance 5 (31.25 %) 1 (6.25 %) p>0.05 13 (86.67 %) 1 (6.67 %) p<0.001
Sweating 5 (31.25 %) – р<0.05 10 (66.67 %)
– 
p<0.001
Acrocyanosis 4 (25.0 %) – p<0.05 1 (6.67 %)
0 (0.00 %) 
р>0.05
Edema of the lower  
extremities (pastoseness) 13 (81.25 %)
– 
p<0.001 15 (100.0 %)
– 
p<0.001
Note: p – the reliability of the difference in indicators before and after treatment
Table 2
Indicators of psychosocial stress L.Rider in patients with a permanent form of AF 
Level stress, points
Standard therapy 1a group (n=16) Standard therapy + mebicar 1b group (n=15)
Before treatment After treatment Before treatment After treatment
Low 7 (43.75 %) 4 (25.0 %) p>0.05 1 (6.67 %)
1 (6.67 %) 
р>0.05
Average 4 (25.0 %) 7 (43.75 %) p>0.05 7 (46.67 %)
14 (93.33 %) 
p<0.01
High 5 (31.25 %) 5 (31.25 %) p>0.05 9 (60.0 %)
0 (0.00 %) 
p<0.001
Note: p – the reliability of the difference between the indicators before and after treatment
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According to the obtained data of the scale of perceived stress – 10, a high level of stress 
was diagnosed in 8 (53.33 %) persons of group 1b (p<0.01) compared with group 1a. Subjects in 
this group are characterized by increased levels of anxiety, internal conflict, lack of awareness and 
frequent stressful situations. Patients in group 1b after 2 weeks of regular use of mebicar managed 
to relieve stress symptoms (p<0.01) (Table 3). 
Table 3
Indicators of perceived stress-10 in patients with a permanent form of AF
Level stress, points
Standard therapy (n=16) Standard therapy + mebicar (n=15)
Before treatment After treatment Before treatment After treatment
Low 0 (0.00 %) 0 (18.75 %) p>0.05 0 (0.00 %) 
0 (0.00 %) 
р>0.05
Average 14 (87.50 %) 15 (93.75 %) p>0.05 7 (46.67 %)
14 (93.33 %) 
p<0.01
High 2 (12.50 %) 1 (6.25 %) >0.05 8 (53.33 %) 
1 (6.67 %) 
p<0.01
Note: p – the reliability of the difference between the indicators before and after treatment
The HADS hospital scale, along with the assessment of the level of anxiety, allows to de-
termine the level of depression (Table 4). In the examined cohort in 11 (73.33 %) patients with a 
permanent form of AF who received mebicar at the time of the questionnaire there was clinically 
pronounced anxiety (p<0.001) and depression (p>0.05). In 7 (43.75 %) persons of group 1a and in 
1 (6.67 %) persons of group 1b the absence of anxiety was noted (p>0.05). In patients of group 1b 
there was a reduction in anxiety, from clinical to subclinical level (p<0.001), which explains the 
positive dynamics of treatment with mebicar.
Table 4
Іndicators of the hospital scale of anxiety and depression of HADS in patients with a permanent form of AF 
Criteria for
assessing, score
Standard therapy (n=16) Standard therapy + mebicar (n=15)
Before treatment After treatment Before treatment After treatment
Absence of disorder anxiety  
(norm 0–7 points) 7 (43.75 %)
10 (62.50 %) 
p>0.05 1 (6.67 %)
2 (13.33 %) 
p<0.05
Subclinical level anxiety  
(possible case) (8–10) 6 (37.50 %) 5 (31.25 %) p>0.05 3 (20.0 %)
12 (80.0 %) 
p<0.001
Clinical level anxiety  
(probable case) (11 or more) 3 (18.75 %)
1 (6.25 %) 
p>0.05 11 (73.33 %)
1 (6.67 %) 
p<0.001
Absence of disorder depression  
(norm 0–7 points) 3 (18.75 %)
8 (50.0 %) 
p>0.05 1 (6.67 %)
4 (26.67 %) 
p>0.05
Subclinical level depression  
(possible case) (8–10) 7 (43.75 %)
8 (50.0 %) 
p>0.05 3 (20.0 %)
4 (26.67 %) 
p>0.05
Clinical level depression  
(probable case) (11 or more) 4 (25.0 %)
0 (0.00 %) 
р<0.05 11 (73.33 %)
7 (46.67 %) 
p>0.05
Note: p – the reliability of the difference between the indicators before and after treatment 
When evaluating the PHQ-15 health questionnaire (Tab. 5) among patients receiving stan-
dard therapy, the absence of disorder and mild somatization disorder was found in 1 (6.25 %) and 
10 (62.50 %) persons (p>0.05), while in patients taking mebicar this was not observed (p<0,001). 
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However, this group was dominated by moderate and severe somatization disorder in 11 (73.33 %) 
and 4 (26.67 %) people, respectively. Due to the treatment, the proportion of people with these 
disorders decreased to a mild level (p<0.001). Thus, we emphasize the connection between psy-
cho-emotional disorders and cardiovascular pathology: the higher the level of anxiety and depres-
sive symptoms, the worse the health of patients.
Table 5
Indicators of the PHQ-15 health questionnaire in patients with a permanent form of AF
Criteria for assessing health status, 
points
Standard therapy (n=16) Standard therapy + mebicar (n=15)
Before treatment After treatment Before treatment After treatment
Absence of disorder (0–4) 1 (6.25 %) 5 (31.25 %) p>0.05 0 (0.00 %)
1 (6.67 %) 
p>0.05
Light somatization disorder (5–9) 10 (62.50 %) 11 (68.75 %) p>0.05 0 (0.00 %)
14 (93.33 %) 
p<0.001
Moderate somatosis disorder (10–14) 4 (25.0 %) 0 (0.00 %) p<0.05 11 (73.33 %)
0 (0.00 %) 
p<0.001
Severe somatization disorder (15+) 1 (6.25 %) 0 (0.00 %) p>0.05 4 (26.67 %)
0 (0.00 %) 
p<0.05
Note: p – the reliability of the difference between the indicators before and after treatment
The role of social factors, including the influence of the media, political events in the group 
of patients with psycho-emotional symptoms (Table 6). 
Table 6
Indicators that may affect the health of patients with permanent AF
Indexes
Standard therapy (n=16) Standard therapy + mebicar (n=15)
Before treatment After treatment Before treatment After treatment
Deterioration of mutual  
understanding 3 (18.75 %)
1 (6.25 %) 
p>0.05 4 (26.67 %)
7 (46.67 %) 
p>0.05
Reduction of time of joint  
carrying out 0 (0.00 %)
3 (18.75 %) 
p>0.05 4 (26.67 %)
2 (13.33 %) 
p>0.05
The influence of the media 6 (37.50 %) 8 (50.0 %) p>0.05 12 (80.0 %)
5 (33.33 %) 
p<0.01
Political events 12 (75.00 %) 10 (62.50 %) p>0.05 10 (66.67 %) 
2 (13.33 %) 
p<0.01
Note: p – the reliability of the difference between the indicators before and after treatment
As we can see, the activity of catalase was increased in two groups of patients (15.21±1.29 
and 8.74±1.91 mg H2O2/1 ml of blood) (p<0.05) and (17.67±1.50 and 11.11±2.08 mg H2O2/1ml 
of blood) (p<0.05) compared with the norm (9.52–12.92 mg H2O2/1ml of blood). When com-
paring serum superoxide dismutase data, the indicator is statistically higher (p<0.05) and is 
(49.87±1.59 %) and (37.80±5.37 %) (p<0.01), indicating inhibition of the activity of antioxidant 
enzymes. After our treatment, the activity of catalase and superoxide dismutase decreased in 
the respective study group. We found a high level of glutathione peroxidase activity in patients 
receiving anxiolytic therapy, in which the average value is 0.19±0.02 mlmol/min/mg, whereas 
in patients receiving standard therapy, the rate was 0.15±0.04 mlmol/min/mg (p<0.05). Taking 
into account the data of the spectrophotometric method and the titration method, it should be 
noted that the higher the anxiety-depressive symptoms, the higher the rates of free radical 
oxidation are (Table 7).
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Indicators of activity of catalase, glutathione peroxidase (GP), superoxide dismutase (SOD) of blood serum in 
patients with permanent form of AF 
Indexes
Standard therapy (n=16) Standard therapy + mebicar (n=15)
Before treatment After treatment Before treatment After treatment






SOD, % 34.81±4.03 27.13±6.04 p<0.05 49.87±1.59
37.80±5.37 
p<0.01
GP, mlmol, min/mg 0.15± 0.02 0.15±0.04 p>0.05 0.19±0.02
0.16±0.03
p>0.05
Note: p – the reliability of the difference between the indicators before and after treatment
Analyzing the levels of cortisol (Table 8), we observed an increase in it, depending on 
the level of anxiety-depressive symptoms and stress susceptibility. In patients 1b, this figure 
is 20.18±3.79 μg/dl and 11.99±1.12 μg/dl (p<0.05), which indicates an increased degree of psy-
cho-emotional stress. Thus, we see that the higher the level of psychological stress, the higher the 
rate of total serum cortisol compared to the standard treatment group (p>0.05).
Table 8
Dynamics of serum cortisol index in patients with permanent form of AF in the process of treatment with 
mebicar
Indexes
Standard therapy (n=16) Standard therapy + mebicar (n=15)
Before treatment After treatment Before treatment After treatment
Cortisol, μg/dL 11.71±1.53 10.59±2.00 p>0.05 20.18±3.79
11.99±1.12 
p<0.05
Note: p – the reliability of the difference between the indicators before and after treatment
As shown by enzyme-linked immunosorbent assay, the tendency to increase NT-proBNP 
is not observed (Table 9). However, it was found that in the group of patients with anxiety and 
depressive symptoms, the level of NT-proBNP increased from 21.29±1.29 to 26.74±4.91 ng/ml 
(p>0.05), whereas in in the standard treatment group this was not observed. When evaluating 
NT-proBNP digital data, it should be borne in mind that mebicar does not affect the manifesta-
tions of heart failure.
Table 9
Indicator of natriuretic peptide (BNP) and the N-terminal fragment of the precursor of the brain natriuretic 
peptide in serum (NT-proBNP) in patients with a permanent form of AF 
Indexes
Standard therapy (n=16) Standard therapy+ mebicar (n=15)
Before treatment After treatment Before treatment After treatment
Natriuretic peptide (BNP) and N-terminal 
fragment of serum sodium natriuretic peptide 
precursor (NT-proBNP), ng /ml.
21.58±1.58 21.82±1.82 р>0.05 21.29±1.29
26.74±4.91 
р>0.05 
Note: p – the reliability of the difference between the indicators before and after treatment
5. Discussion 
The results of multicenter studies confirm that the prevalence of new AF cases doubles 
every year and is 1.5 times higher in men that in women [15, 16]. It has been established that 
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70–80 % of patients with rhythm disturbance have borderline psychiatric disorders, in partic-
ular, anxiety and depression, which aggravate the course of AF [18]. The Framingham study 
demonstrated that tension, negative emotions are independent predictors of cardiovascular 
events [19, 20].
Among the prognostic markers of increased paroxysms of arrhythmia, an important role 
belongs to the symptoms of depressions, which is manifested by changes in psycho-emotional 
state [21–23]. These symptoms have been shown to increase the risk of death in patients, but the 
association with AF has been relatively limited [17].
According to the results of the study, the reception of a medical practitioner contributed to 
the reduction of anxiety-depressive symptoms and the level of psycho-emotional load, which cre-
ates a favorable course of the main disease. Thus, the changer we found in the spectrum of clinical 
and hemodynamic parameters established the relationship between psychopathological disorders 
and the constant from of atrial fibrillation.
Limitations of the study. The study was conducted during 2018–2019. The study included 
all patients older than 20 years old with the diagnosis of atrial fibrillation from Februare 2018 to 
Februare 2019. 
The prospect for further research is the study of the relationship of psycho-emotional 
states on the development of paroxysm atrial fibrillation.
5. Conclusion
1. The inclusion of mebicar in the standard treatment of atrial fibrillation in patients with 
anxiety and depressive symptoms potentiates the manifestations of astheno-autonomic syndrome, 
helps reduce stress, anxiety and depression, promotes dynamics of stress with a decrease in the 
initial concentration of cortisol.
2. The use of mebicar in the treatment of patients with atrial fibrillation can reduce the vi-
olation of lipid peroxidation, blood levels of cortisol, which is clinically manifested by a positive 
correction of anxiety disorders and depression.
3. No significant effect of mebicar on the level of markers of heart failure in patients with 
atrial fibrillation was found.
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